Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO Sells $21,421.40 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 715 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $29.96, for a total value of $21,421.40. Following the transaction, the chief accounting officer now directly owns 36,643 shares of the company’s stock, valued at $1,097,824.28. The trade was a 1.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

James George Chopas also recently made the following trade(s):

• On Monday, January 13th, James George Chopas sold 783 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total transaction of $22,472.10.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $30.13 on Wednesday. The company’s fifty day moving average price is $31.89 and its 200-day moving average price is $33.31. The stock has a market cap of $3.75 billion, a PE ratio of -14.84 and a beta of 0.94. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same period in the previous year, the firm earned ($1.17) EPS. The company’s revenue was up 78.3% on a year-over-year basis. On average, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in APLS. HighVista Strategies LLC boosted its position in shares of Apellis Pharmaceuticals by 4.1% in the second quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock worth $290,000 after purchasing an additional 300 shares during the period. Amalgamated Bank lifted its stake in shares of Apellis Pharmaceuticals by 5.4% during the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after buying an additional 359 shares in the last quarter. KBC Group NV boosted its holdings in Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after buying an additional 679 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after buying an additional 781 shares in the last quarter. Finally, Wolverine Asset Management LLC bought a new stake in Apellis Pharmaceuticals during the third quarter valued at about $27,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on APLS. Robert W. Baird cut their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Mizuho cut their price target on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. The Goldman Sachs Group cut shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective on the stock. in a research report on Tuesday, December 17th. Scotiabank dropped their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a report on Wednesday, November 6th. Finally, HC Wainwright restated a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).